<DOC>
	<DOCNO>NCT02024646</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy brodalumab , compare placebo , subject psoriatic arthritis . The key secondary objective evaluate efficacy brodalumab compare placebo week 16 . The safety objective study evaluate safety profile brodalumab subject psoriatic arthritis .</brief_summary>
	<brief_title>Study Efficacy Safety Brodalumab Subjects With Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects diagnosis psoriatic arthritis ( Classification Psoriatic Arthritis criterion ( CASPAR ) , ≥ 3 tender ≥ 3 swollen joint ( exclude distal interphalangeal joint ) . Subjects must least 1 psoriatic skin lesion . • Subject know history active tuberculosis . Subject plan surgical intervention baseline week 52 evaluation . Subject active infection history infection . Subject systemic disease ( eg , renal failure , heart failure , hypertension , liver disease , diabetes , anemia ) consider Investigator clinically significant uncontrolled . Subject concurrent medical condition electrocardiogram ( ECG ) abnormality , opinion investigator , could cause study detrimental subject . Subject severe depression measure Personal Health Questionnaire Depression Scale ( PHQ8 ) suicidal ideation/behavior measure Columbia Suicide Severity Rating Scale ( eCSSRS ) • Subject history evidence psychiatric disorder substance abuse consider Investigator pose risk subject safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Brodalumab</keyword>
	<keyword>AMG 827</keyword>
</DOC>